Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Egyptian Atomic Energy Authority (EAEA) EGFR compound 6
- Development stage
- Preclinical
- Lead developer
- Egyptian Atomic Energy Authority
01
Overview
Egyptian Atomic Energy Authority (EAEA) EGFR compound 6: sourced facts only. name: "Similarly, compound 6 exhibited a promising EGFR inhibitory activity with the lowest IC50 (0.065 μM) compared to erlotinib (IC50 0.061 μM)." [PMID:41175725]; target: "Similarly, compound 6 exhibited a promising EGFR inhibitory activity with the lowest IC50 (0.065 μM) compared to erlotinib (IC50 0.061 μM)." [PMID:41175725]; developer: "Department of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Cairo 11787, Egypt." [PMID:41175725]; stage: "Compound 6 revealed the most potent cytotoxic activity (IC50 = 4.55 μM) compared to doxorubicin (IC50 = 7.52 μM) on A-549 cell line." [PMID:41175725]
02
Targets
Beyond the preview
Go deeper on Egyptian Atomic Energy Authority (EAEA) EGFR compound 6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Egyptian Atomic Energy Authority (EAEA) EGFR compound 6.